- Active not recruitingPHASE3
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
This study, called LUCIA, is looking at a new treatment called EYP-1901 for wet age-related macular degeneration (wAMD). Researchers want to see if EYP-1901 is as effective as a standard treatment, aflibercept, over two years for improving or maintaining eyesight.
For: Wet Age Related Macular Degeneration · wAMDUnited States · Brazil · Czechia - RecruitingPHASE3
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
This study is testing a new eye treatment, EYP-1901, against an existing one, Aflibercept, for people with diabetic macular edema (DME). It aims to see if the new treatment works just as well to improve or keep vision stable.
For: Diabetic Macular Edema · DME · Diabetic Macular Edema (DME)United States · Brazil · Czechia